Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug

MT Newswires Live02-07

Shanghai Henlius Biotech (HKG:2696) agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) in the US and 42 European countries.

HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.

Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.

Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2509797096?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-07 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509797096","market":"sh","top_or_hot":-1,"title":"Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug","media":"MT Newswires Live","content":"<html><body><p> Shanghai Henlius Biotech (HKG:2696) agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) in the US and 42 European countries.</p><p>HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.</p><p>Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.</p><p>Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-07 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shanghai Henlius Biotech (HKG:2696) agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) in the US and 42 European countries.</p><p>HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.</p><p>Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.</p><p>Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509797096","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509797096","pubTimestamp":1738920871,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Henlius Biotech  agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories  in the US and 42 European countries.HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖","BK1161":"生物科技"},"translate_title":"复宏汉霖生物与Dr.Reddy's达成骨髓瘤药物许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech (HKG:2696) agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) in the US and 42 European countries.HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2509797096"}